Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2013

Open Access 01-12-2013 | Research

Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D

Authors: Paulos Teckle, Helen McTaggart-Cowan, Kim Van der Hoek, Stephen Chia, Barb Melosky, Karen Gelmon, Stuart Peacock

Published in: Health and Quality of Life Outcomes | Issue 1/2013

Login to get access

Abstract

Objective

To help facilitate economic evaluations of oncology treatments, we mapped responses on cancer-specific instrument to generic preference-based measures.

Methods

Cancer patients (n = 367) completed one cancer-specific instrument, the FACT-G, and two preference-based measures, the EQ-5D and SF-6D. Responses were randomly divided to form development (n = 184) and cross-validation (n = 183) samples. Relationships between the instruments were estimated using ordinary least squares (OLS), generalized linear models (GLM), and censored least absolute deviations (CLAD) regression approaches. The performance of each model was assessed in terms of how well the responses to the cancer-specific instrument predicted EQ-5D and SF-6D utilities using mean absolute error (MAE) and root mean squared error (RMSE).

Results

Physical, functional, and emotional well-being domain scores of the FACT-G best explained the EQ-5D and SF-6D. In terms of accuracy of prediction as measured in RMSE, the CLAD model performed best for the EQ-5D (RMSE = 0.095) whereas the GLM model performed best for the SF-6D (RMSE = 0.061). The GLM predicted SF-6D scores matched the observed values more closely than the CLAD and OLS.

Conclusion

Our results demonstrate that the estimation of both EQ-5D and SF-6D utility indices using the FACT-G responses can be achieved. The CLAD model for the EQ-5D and the GLM model for the SF-6D are recommended. Thus, it is possible to estimate quality-adjusted life years for economic evaluation from studies where only cancer-specific instrument have been administered.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Levine MN, Ganz PA, Haller DG: Economic evaluation in the journal of clinical oncology: past, present, and future. J Clin Oncol 2007,25(6):614–616. 10.1200/JCO.2006.10.1659CrossRef
4.
Raftery JP: Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Med J Aust 2008,188(1):26–28.PubMed
5.
Guidelines for the economic evaluation of health technologies: Canada. 3rd edition. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006.
6.
Claxton K, Sculpher M, Drummond M: A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet 2002,360(9334):711–715. 10.1016/S0140-6736(02)09832-XPubMedCrossRef
7.
Gafni A, Birch S: NICE methodological guidelines and decision making in the National Health Service in England and Wales. Pharmacoeconomics 2003,21(3):149–157. 10.2165/00019053-200321030-00001PubMedCrossRef
8.
Scuffham PA, Whitty JA, Mitchell A, Viney R: The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian pharmaceutical benefits scheme 2002–4. Pharmacoeconomics 2008,26(4):297–310. 10.2165/00019053-200826040-00003PubMedCrossRef
9.
Taylor R: Using health outcomes data to inform decision-making: government agency perspective. Pharmacoeconomics 2001,19(2):33–38.PubMedCrossRef
10.
Tilson L, Barry M: European Pharmaceutical Pricing and Reimbursement Strategies. National Centre for Pharmacoeconomics in Ireland: Dublin; 2005.
11.
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al.: The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993, 11: 570–579.PubMed
12.
Brazier JE, Roberts J: The estimation of a preference-based measure of health from the SF-12. Med Care 2004,42(9):851–859. 10.1097/01.mlr.0000135827.18610.0dPubMedCrossRef
13.
Dolan P: Modeling valuations for EuroQol health states. Med Care 1997, 35: 1095–1108. 10.1097/00005650-199711000-00002PubMedCrossRef
14.
Wiebe S, Guyatt G, Weaver B, Matijevic S, Sidwell C: Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol 2003,56(1):52–60. 10.1016/S0895-4356(02)00537-1PubMedCrossRef
15.
Brazier J, Yang Y, Tsuchiya A, Rowen DL: A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ 2009.
16.
Mortimer D, Segal L: Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decis Making 2008,28(1):66–89.PubMedCrossRef
17.
Adams R, Walsh C, Veale D, Bresnihan B, FitzGerald O, Barry M: Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis. Pharmacoeconomics 2010,28(6):477–487. 10.2165/11533010-000000000-00000PubMedCrossRef
18.
Bansback N, Marra C, Tsuchiya A, Anis A, Guh D, Hammond T, et al.: Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Rheum 2007,57(6):963–971. 10.1002/art.22885PubMedCrossRef
19.
Brazier JE, Kolotkin RL, Crosby RD, Williams GR: Estimating a preference-based single index for the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) instrument from the SF-6D. Value Health 2004,7(4):490–498. 10.1111/j.1524-4733.2004.74012.xPubMedCrossRef
20.
Brazier J, Czoski-Murray C, Roberts J, Brown M, Symonds T, Kelleher C: Estimation of a preference-based index from a condition-specific measure: the king’s health questionnaire. Med Decis Making 2008,28(1):113–126.PubMedCrossRef
21.
Buxton MJ, Lacey L, Feagan B, Niecko T, Miller D, Townsend R: Mapping from disease-specific measures to utility: an analysis of the relationships between the inflammatory bowel disease questionnaire and crohn‘s disease activity index in crohn’s disease and measures of utility. Value Health 2007,10(3):214–220. 10.1111/j.1524-4733.2007.00171.xPubMedCrossRef
22.
Cheung YB, Thumboo J, Gao F, Ng GY, Pang G, Koo WH, et al.: Mapping the English and Chinese versions of the functional assessment of cancer therapy-general to the EQ-5D utility index. Value Health 2009,12(2):371–376. 10.1111/j.1524-4733.2008.00448.xPubMedCrossRef
23.
Fryback DG, Lawrence WF, Martin PA, Klein R, Klein BEK: Predicting quality of well-being scores from the SF-36: results from the Beaver dam health outcomes study. Med Decis Making 1997,17(1):1–9. 10.1177/0272989X9701700101PubMedCrossRef
24.
Koltowska-Haggstrom M, Jonsson B, Isacson D, Bingefors K: Using EQ-5D to derive general population-based utilities for the quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA). Value Health 2007,10(1):73–81. 10.1111/j.1524-4733.2006.00146.xPubMedCrossRef
25.
Kontodimopoulos N, Aletras VH, Paliouras D, Niakas D: Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value Health 2009,12(8):1151–1157. 10.1111/j.1524-4733.2009.00569.xPubMedCrossRef
26.
Sauerland S, Weiner S, Dolezalova K, Angrisani L, Noguera C, García-Caballero M, et al.: Mapping utility scores from a disease-specific quality-of-life measure in bariatric surgery patients. Value Health 2008,12(2):364–370.CrossRef
27.
Lin FJ, Longworth L, Pickard AS: Evaluation of content on EQ-5D as compared to disease-specific utility measures. Qual Life Res 2013,22(4):853–874. 10.1007/s11136-012-0207-6PubMedCrossRef
28.
McTaggart-Cowan H, Teckle P, Peacock S: Mapping utilities from cancer-specific health-related quality of life instruments: a review of the literature. Expert Rev Pharmacoecon Outcomes Res 2013. In Press
29.
Wong CKH, Lam CLK, Rowen D, McGhee SM, Ma KP, Law WL, et al.: Mapping the functional assessment of cancer therapy-general or -colorectal to SF-6D in Chinese patients with colorectal neoplasm. Value Health 2012, 15: 495–503. 10.1016/j.jval.2011.12.009PubMedCrossRef
30.
Wu EQ, Mulani P, Farrell MH, Sleep D: Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value Health 2007,10(5):408–414. 10.1111/j.1524-4733.2007.00195.xPubMedCrossRef
31.
32.
Brooks R: EuroQol: the current state of play. Health Policy 1996, 37: 53–72. 10.1016/0168-8510(96)00822-6PubMedCrossRef
33.
Shaw J, Johnson JA, Coons SJ: US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005,43(3):203–220. 10.1097/00005650-200503000-00003PubMedCrossRef
34.
Brazier J, Usherwood T, Harper R, Thomas K: Deriving a preference-based single index from the UK SF-36 health survey. J Clin Epidemiol 1998, 51: 1115–1128. 10.1016/S0895-4356(98)00103-6PubMedCrossRef
35.
Lawrence WF, Fleishman JA: Predicting EuroQoL EQ-5D preference scores from the SF-12 health survey in a nationally representative sample. Med Decis Making 2004,24(2):160–169. 10.1177/0272989X04264015PubMedCrossRef
36.
Franks P, Lubetkin EI, Marthe RG, Tancredi DJ: Mapping the SF-12 to preference-based instruments: convergent validity in a low-income, minority population. Medical Care 2003,41(11):1277–1283. 10.1097/01.MLR.0000093480.58308.D8PubMedCrossRef
37.
Franks P, Lubetkin EI, Gold MR, Tancredi DJ, Jia H: Mapping the SF-12 to the EuroQol EQ-5D index in a national US sample. Med Decis Making 2004,24(3):247–254. 10.1177/0272989X04265477PubMedCrossRef
38.
Longworth L, Buxton M, Sculpher M, Smith D: Estimating utility data from clinical indicators for patients with stable angina. Eur J Health Econ 2005,6(4):347–353. 10.1007/s10198-005-0309-yPubMedCrossRef
39.
McKenzie L, van der Pol M: Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data. Value Health 2008,12(1):167–171.PubMedCrossRef
40.
Nichol MB, Sengupta N, Globe DR: Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36. Med Decis Making 2001,21(2):105–112.PubMedCrossRef
41.
Sullivan PW, Ghushchyan V: Mapping the EQ-5D Index from the SF-12: US general population preferences in a nationally representative sample. Med Decis Making 2006,26(4):401–409. 10.1177/0272989X06290496PubMedCentralPubMedCrossRef
42.
Powell JL: Least absolute deviations estimation for the censored regression-model. J Econ 1984,25(3):303–325. 10.1016/0304-4076(84)90004-6CrossRef
43.
Huang IC, Frangakis C, Atkinson MJ, Willke RJ, Leite WL, Vogel WB: Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease. Health Serv Res 2008,43(1p1):327–339.PubMedCentralPubMedCrossRef
44.
Hyndman RJ, Koehler AB: Another look at measures of forecast accuracy. International Journal of Forecasting 2010,22(4):679–688.CrossRef
45.
StataCorp: Stata Statistical Software: Release 11.0 for Windows. Texas: College Station; 2010.
46.
Teckle P, Peacock S, McTaggart-Cowan H, van der Hoek K, Chia S, Melosky B, et al.: The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities. Health Qual Life Outcomes 2011,9(1):106. 10.1186/1477-7525-9-106PubMedCentralPubMedCrossRef
47.
Dolan P, Kahneman D: Interpretations of utility and their implications for the valuation of health. Econ J 2008,118(525):215–234.CrossRef
48.
Brazier J, Akehurst R, Brennan A, Dolan P, Claxton K, McCabe C, et al.: Should patients have a greater role in valuing health states? Appl Health Econ Health Policy 2005,4(4):201–208. 10.2165/00148365-200504040-00002PubMedCrossRef
49.
50.
Jang RW, Isogai PK, Mittmann N, Bradbury PA, Shepherd FA, Feld R: Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire Values in Lung Cancer. J Thorac Oncol 2010,5(12):1953–1957. 10.1097/JTO.0b013e3181f77a6aPubMedCrossRef
51.
Johnson JA, Pickard ASB: Comparison of the EQ-5D and SF-12 Health Surveys in a General Population Survey in Alberta, Canada. Medical Care 2000,38(1):115–121. 10.1097/00005650-200001000-00013PubMedCrossRef
52.
Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, et al.: A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005,60(7):1571–1582. 10.1016/j.socscimed.2004.08.034PubMedCrossRef
53.
Rabin R, de Charro F: EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001,33(5):337–343. 10.3109/07853890109002087PubMedCrossRef
Metadata
Title
Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D
Authors
Paulos Teckle
Helen McTaggart-Cowan
Kim Van der Hoek
Stephen Chia
Barb Melosky
Karen Gelmon
Stuart Peacock
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2013
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-11-203

Other articles of this Issue 1/2013

Health and Quality of Life Outcomes 1/2013 Go to the issue

Research

Health promoting schools and children’s oral health related quality of life

Research

Does the care dependency of nursing home residents influence their health-related quality of life?-A cross-sectional study

Research

A UK validation of a general measure of subjective well-being: the modified BBC subjective well-being scale (BBC-SWB)

Research

Analysis, evaluation and adaptation of the ReTransQoL: a specific quality of life questionnaire for renal transplant recipients

Research

The impact of resilience on psychological outcomes in women after preeclampsia: an observational cohort study

Commentary

The case for an international patient-reported outcomes measurement information system (PROMIS®) initiative